A CATALIST-LISTED medtech firm that made strong gains this year as investors hunted for exposure to tech plays and Covid-19 test makers, has now claimed that a Japanese group breached intellectual property-related (IP) agreements.

BIOLIDICS has issued a letter of demand to Japan-based healthcare group Sysmex Corporation, it said in a bourse filing on Friday.

THE following companies saw new developments that may affect trading of their shares on Monday:

PhillipCapital has maintained its “buy” rating and target price of 26 cents on ClearBridge Health (CBH) on the back of a stronger 2H20 for the company.  The Phillip Research Team said 1H20 revenue and earnings before interest, taxes, depreciation, and amortization (EBITDA) were within expec...

COVID-19 test kit maker Biolidics said late on Thursday that it anticipates it will take up to nine months to incorporate technology it recently licensed from the Agency for Science, Technology and Research (A*Star) into a new serology test kit.

COVID-19 test kit maker Biolidics said late on Thursday that it anticipates it will take up to nine months to incorporate technology it recently licensed from the Agency for Science, Technology and Research (A*Star) into a new serology test kit.

THE following companies saw new developments that may affect trading of their securities on Friday:

THE following companies saw new developments that may affect trading of their securities on Thursday:

THE Singapore Exchange (SGX) on Wednesday posed a series of queries to Biolidics about the details of a licence agreement the Catalist-listed firm had inked as well as the timing of its trading halt and announcement.

SINGAPORE (July 15): Singapore-based medical technology firm Biolidics has prompted a query from the Singapore Exchange Regulation (SGX RegCo) following the delayed announcement of its licensing agreement with Accelerate Technologies. In the query at 2.31pm on Wednesday, SGX RegCo has asked Biolidic...